FDA granted Virtuoso Surgical a De Novo authorization for its transurethral robotic system, the company said November 10. The authorization covers urologic surgery in the bladder where a transurethral approach is appropriate, and the collection of bladder tissue specimens, including detrusor muscle, to help diagnose bladder cancer.

Two needle-sized arms built from concentric superelastic nitinol tubes sit at the tip of a rigid endoscope and run from a surgeon console. One arm lifts and retracts the lesion while the other dissects beneath it. The goal is a single intact specimen instead of the fragments a conventional resectoscope leaves.

In the first 20 patients of the VIABLE study (NCT06940648), detrusor muscle was present in 94 percent of resected lesions, against a prespecified performance goal of 60 percent. Margins were evaluable in 93 percent of malignant lesions, and the company reported no intraoperative adverse events. The six-patient first phase, published in European Urology Oncology in February 2026, reported a mean procedure time of 52 minutes and no bladder perforations.

The classification is worth more to the field than this one clearance. FDA created a new device type for electromechanical surgical systems used in endoluminal procedures. The next endoluminal robot now has a predicate and a 510(k) to aim at rather than its own De Novo. Virtuoso took a Breakthrough designation in September 2025 and plans a focused US launch at urology centers in 2027.